Abstract: Phenyl cyclohexanone based active agents, pharmaceutical preparations containing such active agents, methods of modifying cellular activity by contacting cells with such active agents, and methods of treating various conditions by administering such active agents to a patient are described.
Abstract: Compounds are provided having one of the following structures (I) or (II): or (I) (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R3a, R3b, L1, L2, G1a, G1b, G2a, G2b and G3 are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Abstract: The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them: wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.
Type:
Grant
Filed:
December 6, 2021
Date of Patent:
November 21, 2023
Assignee:
BIOGEM S.C. A R.L.
Inventors:
Claudio Pisano, Sabrina Dallavalle, Raffaella Cincinelli, Lucio Merlini
Abstract: Novel Schiff base and diazo liquid crystals with a selenium center forming nanostructured Cubbi phases are presented herein. The new liquid crystals can be used for the fabrication of high-performance photovoltaic devices, while exhibiting improved thermal stability and electron-transport properties as compared to currently known liquid crystals.
Type:
Grant
Filed:
June 21, 2023
Date of Patent:
November 14, 2023
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Saadeldin Elsayed Ibrahim Shabaan, Hany Mohamed Abd El-Lateef Ahmed, Mohamed Alaasar
Abstract: A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a sonosensitizing compound containing at least one transition metal with three bidentate ligands; and (b) exposing the sonosensitizing compound in the organism to ultrasound, wherein the ultrasound is effective to activate the sonosensitizing compound to destroy at least one of the cells and the microorganisms in the organism. The ultrasound is preferably used in conjunction with electromagnetic therapies comprising photodynamic therapy, low-level laser therapy, and radiation therapy. The ultrasound is preferably administered at a duty cycle in the range from 5% to 95% at a power density of 10 W/cm2 and a frequency in the range from 10 Hz to 10 MHz.
Abstract: The objective of the invention is to provide a polycyclic aromatic compound in which solubility to a solvent, film formability, wet coatability, thermal stability, and in-plane orientation are improved. This objective is achieved by alight emission layer-forming composition comprising: as a first component, at least one type of dopant material selected from the group consisting of polycyclic aromatic compounds represented by general formula (A) and polycyclic aromatic oligomer compounds including a plurality of structures represented by general formula (A); as a second component, a specific low-molecular-weight host material; and, as a third component, at least one type of organic solvent. In formula (A), ring A, ring B, and ring C each independently represent an aryl ring or a hetero aryl ring, Y1 is B, and X1 and X2 each independently represent O or N—R wherein at least one of X1 and X2 is N—R.
Type:
Grant
Filed:
August 27, 2021
Date of Patent:
November 7, 2023
Assignees:
Kwansei Gakuin Educational Foundation, SK Materials JNC Co., Ltd.
Abstract: The present invention provides a method for improving the stability of pramipexole or its salt preparation, and further provides a pramipexole hydrochloride oral liquid with excellent stability and oral absorption effect. The pramipexole hydrochloride oral liquid of the present invention is prepared through a simple process, and shows bioequivalence with the tablet containing pramipexole hydrochloride. The invention perfectly realizes multi-dose administration of pramipexole hydrochloride and improves the compliance and accessibility of medication for patients.
Abstract: The present disclosure relates to novel two-dimensional halide perovskite materials, and the method of making and using the two-dimensional halide perovskite materials.
Abstract: The present invention relates to a new family of titanium heterometallic structured metal-organic materials (MOFs) having, among other characteristics, high porosity, stability in an aqueous medium and photocatalytic activity under visible light and UV radiation. The new family of materials has a structural unit that combines tetravalent titanium with multiple combinations of divalent metals with a homogeneous distribution at atomic level in the MOF structure. The invention also relates to methods for obtaining them with high yields, in addition to their uses in the generation of solar fuels, photoactivated degradation, photoreduction of CO2, heterogeneous catalysis, as a component or part of an electronic component and/or as a porous or photoactive coating for controlling pollutants, inter alia.
Type:
Grant
Filed:
May 23, 2019
Date of Patent:
October 17, 2023
Assignees:
Universitat de València, Universidad de Granada
Inventors:
Carlos Marti Gastaldo, Javier Castells Gil, Natalia Muñoz Padial
Abstract: Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with ?-lactamase inhibitors and/or other antibiotics (including ?-lactam and non-?-lactam antibiotics) in the treatment or prevention of bacterial infections.
Type:
Grant
Filed:
March 29, 2022
Date of Patent:
October 10, 2023
Assignee:
FEDORA PHARMACEUTICALS INC.
Inventors:
Renata Jankowska, Sameeh M. Salama, Samarendra N. Maiti
Abstract: This document relates to functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such functionalized polymers.
Abstract: Provided is a method of stabilizing a perfluorodioxolane compound, which includes having a quinone compound present in a composition containing a perfluorodioxolane compound, wherein the perfluorodioxolane compound is one or more perfluorodioxolane compounds selected from the group consisting of a perfluorodioxolane compound denoted by general formula (1) and a perfluorodioxolane compound denoted by general formula (2).
Abstract: A binuclear Fe(III) fused porphyrin. Synthesizing the binuclear fused porphyrin includes combining free-base fused-porphyrin and a solvent to yield a solution, refluxing the solution, combining a metal salt with the solution, and removing the solvent from the solution.
Type:
Grant
Filed:
September 14, 2022
Date of Patent:
September 12, 2023
Assignee:
Arizona Board of Regents on behalf of Arizona State University
Abstract: The present disclosure provides creatine prodrug analogs and their compositions useful for the treatment of creatine deficiencies.
Type:
Grant
Filed:
March 28, 2022
Date of Patent:
September 12, 2023
Assignee:
Ultragenyx Pharmaceutical Inc.
Inventors:
Yiumo Chan, Emil D. Kakkis, Alexandra Trotier-Faurion, William F. Brubaker, Arjun Natesan, Paul Lee, Sharyl Fyffe-Maricich, David Lapointe, Mike E. Lizarzaburu
Abstract: A coloring composition includes a metal azo pigment, a compound having an ethylenically unsaturated bonding group, and a solvent, the metal azo pigment includes at least one kind of an anion selected from an azo compound represented by Formula (I) or an azo compound having a tautomeric structure of the azo compound represented by Formula (I), two or more kinds of metal ions, and a melamine compound, and in Formula (I), R1 and R2 each independently represent OH or NR5R6, R3 and R4 each independently represent ?O or ?NR7, and R5 to R7 each independently represent a hydrogen atom or an alkyl group.
Abstract: Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of ?-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.
Type:
Grant
Filed:
January 25, 2022
Date of Patent:
September 5, 2023
Assignee:
PTC Therapeutics, Inc.
Inventors:
Andrew W. Hinman, Charles R. Holst, Angela Minnella, Paul Mollard, Sean Pintchovski, Jeffrey K. Trimmer, Eric Torrey
Abstract: The invention provides novel polymer-protein conjugates and molecular assemblies for controlled intracellular delivery of proteins, and compositions and methods of preparation and use thereof.